Live tape
Top 8, mentions 7d11,451SPCX2,428 mentions▲ +0.08GOOGL1,984 mentions▲ +0.02META1,790 mentions▲ +0.04TSLA1,704 mentions▲ +0.05NFLX973 mentions▲ +0.03QQQ886 mentions▲ +0.05AMZN844 mentions▲ +0.06NVDA842 mentions▲ +0.06

Equity · Healthcare

RPRX

NASDAQ

Royalty Pharma (RPRX)

$57.14 −0.86% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 2, 2026
Price · Chart
40 sessions
$65.0 $55.0 7 Aug 2 Oct

The line runs $56.79 on 7 August through $57.14 on 2 October, on a scale from $55.0 to $65.0. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 40 sessions, 7 Aug – 2 Oct 2026
Market cap $31.8B
P/E (TTM) 30.6
52-week range $35 – $64
Avg volume 200.5K

as of Oct 2, 2026

Royalty Pharma (RPRX) insider trades

SEC Form 4 · last 90 days · newest reported trade 5 Oct 2026

In the 90 days to 26 Oct 2026, Royalty Pharma insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 30 Sep 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 5
Net sold $12.97M
Non-trade filings 6
Date Insider Type Shares Value
05 Oct 2026 Urist Marshall EVP, Research & Investments Sell 4,126 $236K
28 Sep 2026 Urist Marshall EVP, Research & Investments Sell 4,126 $239K
22 Sep 2026 Hite Christopher EVP & Chairman, Partnering Sell 100,000 $5.85M
18 Aug 2026 Hite Christopher EVP & Chairman, Partnering Sell 100,000 $6.00M
13 Aug 2026 Coyne Terrance P. EVP & CFO Sell 11,002 $646K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
30 Sep 2026 Bassler Bonnie L Director Award 642 $37K
19 Aug 2026 Hite Christopher EVP & Chairman, Partnering Gift 16,800
05 Aug 2026 Coyne Terrance P. EVP & CFO Award 11,002
05 Aug 2026 Hite Christopher EVP & Chairman, Partnering Award 11,002
05 Aug 2026 Legorreta Pablo G. CEO, Chairman of the Board Award 65,216
05 Aug 2026 Urist Marshall EVP, Research & Investments Award 8,252

Royalty Pharma (RPRX) reported financials

SEC EDGAR XBRL SEC EDGAR

Royalty Pharma reported revenue of $2.4B for the fiscal year ended 31 Dec 2025. Net income over the same period was $770.9M.

Figure Reported Period
Revenue $2.4B 31 Dec 2025 fiscal year
Net income $770.9M 31 Dec 2025 fiscal year
Diluted EPS $1.78 31 Dec 2025 fiscal year
Total assets $19.8B 30 Jun 2026 at period end
Total equity incl. minority interest $9.8B 30 Jun 2026 at period end

Royalty Pharma (RPRX) earnings

SEC EDGAR

Royalty Pharma last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.04; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.04 $674M
31 Mar 2026 Q1 2026 $0.67 $631M
31 Dec 2025 FY 2025 $1.78 $2.38B
30 Sep 2025 Q3 2025 $0.67 $609M
30 Jun 2025 Q2 2025 $0.07 $579M
31 Mar 2025 Q1 2025 $0.55 $568M
31 Dec 2024 FY 2024 $1.91 $2.26B
30 Sep 2024 Q3 2024 $1.21 $565M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Royalty Pharma (RPRX) institutional holders (13F)

SEC Form 13F SEC EDGAR

11 of the 45 institutional funds we track reported a Royalty Pharma position for the quarter ended 30 Jun 2026 — a combined $819.0M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Held (±25%) +13.8% shares 4,305,412 $241.4M
Two Sigma Investments Added +29.7% shares 2,920,163 $163.7M
Marshall Wace Held (±25%) +15.6% shares 2,450,669 $137.4M
Renaissance Technologies Added +144.7% shares 1,935,800 $108.5M
Citadel Advisors Trimmed −49.5% shares 1,354,640 $76.0M
Tudor Investment Corp Held (±25%) −9.1% shares 610,736 $34.2M
D. E. Shaw & Co. Trimmed −53.2% shares 525,114 $29.4M
Bridgewater Associates New position 219,687 $12.3M
Man Group Trimmed −58.6% shares 166,593 $9.3M
Point72 Asset Management Trimmed −78.3% shares 106,549 $6.0M

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Royalty Pharma (RPRX) fails-to-deliver

SEC CNS data SEC

On 29 Sep 2026, 1,000 shares of Royalty Pharma failed to deliver (about $58K).

Settlement date Shares failed Notional % of shares out
29 Sep 2026 1,000 $58K <0.001%
23 Sep 2026 549 $32K <0.001%
22 Sep 2026 22,675 $1.3M 0.004%
21 Sep 2026 65,491 $3.8M 0.012%

Royalty Pharma (RPRX): frequently asked questions

From live data

Have Royalty Pharma insiders bought or sold shares recently?

In the 90 days to 26 Oct 2026, Royalty Pharma insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 30 Sep 2025, show no open-market purchase. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold Royalty Pharma?

11 of the 45 institutional funds we track reported a Royalty Pharma position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Royalty Pharma had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Royalty Pharma is dated 29 Sep 2026, when 1,000 shares failed to deliver.

When did Royalty Pharma last report earnings?

Royalty Pharma last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.04; no next date is announced in SEC filings yet.

What exchange is Royalty Pharma listed on?

Royalty Pharma trades on NASDAQ under the ticker RPRX.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings